Vestmark Advisory Solutions Inc. Reduces Position in Recursion Pharmaceuticals, Inc. $RXRX

Key Points

• Vestmark Advisory Solutions Inc. reduced its holdings in Recursion Pharmaceuticals by 16.4%, owning approximately 0.18% of the company after selling 138,915 shares.
• Recursion Pharmaceuticals reported a revenue of $19.10 million for the quarter, which exceeds analyst estimates of $15.38 million, but missed earnings estimates with ($0.41) earnings per share.
• Analysts have a consensus rating of "Hold" on Recursion Pharmaceuticals, with an average target price of $7.00, while Needham & Company maintains a "buy" rating with an $8.00 price objective.

Vestmark Advisory Solutions Inc. decreased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 16.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 706,239 shares of the company's stock after selling 138,915 shares during the quarter. Vestmark Advisory Solutions Inc. owned approximately 0.18% of Recursion Pharmaceuticals worth $3,736,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Man Group plc purchased a new stake in Recursion Pharmaceuticals during the fourth quarter valued at about $479,000. Rockefeller Capital Management L.P. raised its stake in Recursion Pharmaceuticals by 323.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 281,922 shares of the company's stock valued at $1,906,000 after purchasing an additional 215,283 shares in the last quarter. Invesco Ltd. raised its stake in Recursion Pharmaceuticals by 54.6% in the fourth quarter. Invesco Ltd. now owns 178,619 shares of the company's stock valued at $1,207,000 after purchasing an additional 63,068 shares in the last quarter. California State Teachers Retirement System raised its stake in Recursion Pharmaceuticals by 30.7% in the fourth quarter. California State Teachers Retirement System now owns 231,535 shares of the company's stock valued at $1,565,000 after purchasing an additional 54,449 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Recursion Pharmaceuticals by 1.5% during the first quarter. Bank of New York Mellon Corp now owns 863,224 shares of the company's stock valued at $4,566,000 after acquiring an additional 12,588 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the firm's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the transaction, the insider directly owned 668,197 shares in the company, valued at $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 8.43% of the company's stock.

Analyst Upgrades and Downgrades

RXRX has been the topic of several recent analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Morgan Stanley started coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $7.00.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded up $0.0350 during trading hours on Thursday, reaching $4.8050. The company's stock had a trading volume of 6,310,082 shares, compared to its average volume of 24,774,973. The firm's 50-day moving average price is $5.47 and its 200-day moving average price is $5.80. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -2.70 and a beta of 0.93.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The firm had revenue of $19.10 million for the quarter, compared to analysts' expectations of $15.38 million. During the same period last year, the company earned ($0.40) earnings per share. The firm's revenue was up 33.3% on a year-over-year basis. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.